United States · FDA National Drug Code directory
Rinvoq
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0074-2310_e17266e5-c861-46bf-9756-6447566101be
- Product NDC
- 0074-2310
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- Upadacitinib
- Labeler
- AbbVie Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20190816
- Source listing expiry
- 20271231
Source-listed ingredients
- UPADACITINIB — 30 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2310-20) · 0074-2310-20
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2310-30) · 0074-2310-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →